Published in Sci Transl Med on October 13, 2010
The immunological life cycle of tuberculosis. Nat Rev Immunol (2012) 2.25
Mycobacterial PE/PPE proteins at the host-pathogen interface. Clin Dev Immunol (2011) 1.62
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog (2013) 1.54
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol (2011) 1.15
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur J Immunol (2011) 1.14
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol (2011) 1.10
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine (2010) 1.04
Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev (2014) 1.03
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol (2013) 1.03
Vaccine development for tuberculosis: current progress. Drugs (2013) 1.01
Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine (2012) 1.00
Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med (2014) 1.00
Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. PLoS One (2012) 1.00
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunology (2015) 1.00
Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med (2014) 0.97
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun (2011) 0.97
Vaccine adjuvants: mode of action. Front Immunol (2013) 0.94
Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol (2011) 0.94
Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines. Front Immunol (2014) 0.94
Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. Semin Immunol (2014) 0.91
Current and novel approaches to vaccine development against tuberculosis. Front Cell Infect Microbiol (2012) 0.91
Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. J Immunol Methods (2011) 0.91
Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines (2012) 0.91
Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis. Clin Exp Vaccine Res (2014) 0.91
A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One (2014) 0.89
Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One (2013) 0.89
Vaccine against tuberculosis: what's new? BMC Infect Dis (2014) 0.88
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells. J Immunol (2013) 0.88
Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg (2015) 0.86
Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc Natl Acad Sci U S A (2014) 0.86
TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis. Eur J Immunol (2014) 0.86
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog (2014) 0.85
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization. J Control Release (2013) 0.85
Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine (2011) 0.85
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis. J Immunol (2014) 0.84
CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. PLoS Pathog (2016) 0.83
The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis (Edinb) (2015) 0.82
Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells. PLoS One (2015) 0.82
Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis. J Infect Dis (2015) 0.81
Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother (2015) 0.80
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates. PLoS One (2015) 0.79
A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation. Hum Vaccin Immunother (2015) 0.79
Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG. Hum Vaccin Immunother (2014) 0.79
Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis. Infect Immun (2014) 0.79
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun (2016) 0.79
Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity. Oncotarget (2016) 0.78
Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism. J Immunol (2015) 0.78
Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology. Biomed Res Int (2015) 0.78
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine (2015) 0.77
Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine (2015) 0.77
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction. PLoS One (2016) 0.77
The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative. Clin Vaccine Immunol (2014) 0.77
Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate. Clin Vaccine Immunol (2015) 0.76
Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines (Basel) (2014) 0.76
The enigmatic PE/PPE Multi-gene Family of Mycobacteria and TB Vaccination. Infect Immun (2017) 0.76
Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice. Oncotarget (2017) 0.75
Antigen presentation by B cells guides programing of memory CD4(+) T-cell responses to a TLR4-agonist containing vaccine in mice. Eur J Immunol (2016) 0.75
Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci Rep (2017) 0.75
Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis. Ther Adv Vaccines (2017) 0.75
Current status of new tuberculosis vaccine in children. Hum Vaccin Immunother (2016) 0.75
A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis. PLoS One (2016) 0.75
New developments and concepts related to biomarker application to vaccines. Microb Biotechnol (2011) 0.75
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J Control Release (2016) 0.75
Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes. Int J Nanomedicine (2014) 0.75
Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages. Appl Environ Microbiol (2012) 0.75
A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2(+) T Cells. Front Immunol (2017) 0.75
Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection. Sci Rep (2017) 0.75
Immunology of tuberculosis. Annu Rev Immunol (2001) 14.26
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med (1993) 7.85
The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol (2005) 4.52
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21
Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun (2001) 2.62
Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol (2005) 2.08
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine (2010) 1.88
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A (2009) 1.86
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One (2009) 1.66
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin (2009) 1.37
Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One (2009) 1.17
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol (2007) 1.14
Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine (2009) 1.12
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine (2009) 1.12
Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol (2007) 1.11
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine (2009) 1.09
Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine (2005) 1.06
Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect (2009) 1.05
Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c. Infect Immun (2009) 1.01
Design of a novel globular protein fold with atomic-level accuracy. Science (2003) 13.06
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol (2008) 4.31
Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol (2002) 3.74
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother (2005) 3.16
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir Crit Care Med (2003) 2.82
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest (2007) 2.80
The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol (2007) 2.66
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother (2007) 2.50
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother (2003) 2.30
Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J Immunol (2003) 2.25
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun (2003) 2.06
Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 2.05
In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol (2002) 2.04
Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 1.99
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest (2011) 1.89
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A (2009) 1.86
Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun (2003) 1.81
Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun (2006) 1.75
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J Immunol (2007) 1.61
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol (2005) 1.58
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol (2005) 1.56
Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin Diagn Lab Immunol (2002) 1.54
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol (2003) 1.49
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb) (2008) 1.46
Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb) (2009) 1.45
Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol (2007) 1.45
The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg (2002) 1.43
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol (2002) 1.42
Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem (2006) 1.41
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol (2008) 1.39
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother (2010) 1.37
Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-Binding: requirement for establishing chronic persistent infection. PLoS Pathog (2009) 1.37
Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukoc Biol (2010) 1.35
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 1.34
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 1.33
Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am J Respir Cell Mol Biol (2010) 1.33
Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis (2010) 1.28
Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis. Tuberculosis (Edinb) (2006) 1.28
Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) (2011) 1.28
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine (2002) 1.28
Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol (2008) 1.27
Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun (2006) 1.27
Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin Vaccine Immunol (2008) 1.26
Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol (2010) 1.26